India among top global contributors in reporting drug adverse events: DGCI

The week-long campaign aims to sensitise healthcare professionals, regulators, researchers and the public to actively report adverse drug reactions (ADRs) through simplified digital platforms

Indian Flag, India
"Initiation of National Pharmacovigilance Week in the journey of pharmacovigilance in the country has changed the course of pharmacovigilance," Dr Raghuvanshi said while addressing the gathering. (Photo: Shutterstock)
Press Trust of India New Delhi
2 min read Last Updated : Sep 17 2025 | 6:09 PM IST

India ranks among the top contributors globally in reporting adverse events, Drugs Controller General of India (DCGI) Dr Rajeev Raghuvanshi said on Wednesday.

He made the remarks at an event as he highlighted the growing role of pharmacovigilance in safeguarding patient health.

The Indian Pharmacopoeia Commission (IPC), functioning as the National Coordination Centre for the Pharmacovigilance Programme of India (NCC-PvPI), inaugurated the 5th National Pharmacovigilance Week (NPW) at the Bharat Mandapam Convention Centre.

The National Pharmacovigilance Week is being observed from September 17 to September 23 under the theme 'Your Safety, Just a Click Away: Report to PvPI'.

The week-long campaign aims to sensitise healthcare professionals, regulators, researchers and the public to actively report adverse drug reactions (ADRs) through simplified digital platforms.

"Initiation of National Pharmacovigilance Week in the journey of pharmacovigilance in the country has changed the course of pharmacovigilance," Dr Raghuvanshi said while addressing the gathering.

"With the number of reporting, we ranked among the top contributors globally in reporting adverse events", he added.

Highlighting the significance of pharmacovigilance, Dr Raghuvanshi emphasised that "since the inception of the programme, the majority of reports have come from healthcare professionals, whereas meaningful impact can only be achieved when patients themselves actively participate in reporting".

He added that despite the availability of significant data for analysis, its optimum utilisation in strengthening pharmacovigilance is still lacking.

Furthermore, he also said, "The content of pharmacovigilance needs to be changed as the context has changed in the country. It is now that pharmacovigilance has a strong base and policies are being designed and regulated."  He said, "We need to develop a culture of curiosity within the organisation, not a culture of apprehension for better results."  "What is needed is the smart integration of technology and innovative approaches to drive differential thinking," he added.

Underlining the strides made in the direction of pharmacovigilance, Dr Raghuvanshi said, "We have been successful in bringing IPC and IP to the highest agenda of this country."  On this occasion, the IPC unveiled a series of new initiatives, including the launch of a short film on PvPI, a pharmacovigilance comic published in multiple vernacular languages to enhance public awareness and a new online reporting platform designed for easy access through a QR code.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :drugsIndia

First Published: Sep 17 2025 | 6:09 PM IST

Next Story